Global Branded Specialty Business Port-folio Management
-
Insights on ideation of novel branded molecule
-
Disease Modifying Potential
-
505 (b) (2) route with potentially shortest clinical development
-
Single agents or fixed dose combinations.
-
Oral / Topical / intranasal / systemic Routes
-
Patches / nanoparticles Formulations
-
Targeted treatments in Oncology: McAb-drug conjugates
-
Respiratory, Dermatology, Chronic Pain, Cardio-Metabolic and Oncology therapy areas
-
-
Scope of clinical differentiation
-
In-licensing opportunities - Scientific Evaluation and due diligence:
-
Analysis of potential in-licensing opportunities and assets with novel mechanism of action
-
Scientific assessment and insights on first in class and best in class molecules, key differentiation features
-
Respiratory, Dermatology, Chronic Pain, Oncology and Inflammatory disease areas
-
Broad, targeted, orphan or niche indication
-
-
Potential Stake Holders: Pharmaceutical, Biotech and Venture Capital companies